- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on HR Positive/HER-2 Negative Breast Cancer in Singapore
Total 36 results
-
National Cancer Centre, SingaporeMSD Pharma (Singapore) Pte LtdRecruitingHormone Receptor-Positive HER2-Negative Advanced Breast CancerSingapore
-
National University Hospital, SingaporeRecruitingAdvanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast CancersSingapore
-
National University Hospital, SingaporeAdagene IncActive, not recruitingAdvanced Solid Tumor | HER2-negative Breast CancerSingapore
-
Novartis PharmaceuticalsCompletedHormone Receptor Positive, HER2-negative, Advanced Breast CancerJapan, Hong Kong, Singapore
-
University of MalayaNational University Hospital, Singapore; Merck Sharp & Dohme LLC; Cancer Research...RecruitingHER2-Negative Breast CancerSingapore, Malaysia
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
National Cancer Centre, SingaporeCompletedHER 2 Positive Advanced Gastric CancerSingapore
-
National University Hospital, SingaporeMerck Sharp & Dohme LLC; Adagene IncRecruitingTriple Negative Breast Cancer | Advanced Solid TumorSingapore
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
National University Hospital, SingaporeNational Cancer Centre, SingaporeUnknownErbB2-Positive Stage I-III Breast CancerSingapore
-
Novartis PharmaceuticalsCompletedAdvanced HER2-positive Breast CancerFrance, Italy, Germany, Singapore, Sweden, Spain, United Kingdom, United States
-
Gilead SciencesMerck Sharp & Dohme LLCRecruitingTriple Negative Breast Cancer | PD-L1 PositiveUnited States, Taiwan, Belgium, Australia, Austria, Israel, Spain, Italy, Korea, Republic of, Japan, France, Netherlands, Canada, Turkey, Germany, Malaysia, Singapore, United Kingdom, Hong Kong, Hungary, Mexico, Switzerland, Puerto... and more
-
Novartis PharmaceuticalsTerminatedTriple Negative Breast Cancer (TNBC)Netherlands, Spain, Hong Kong, Singapore, Italy, Australia, Israel, Japan, United States
-
Novartis PharmaceuticalsCompletedTriple-negative Breast CancerBelgium, Italy, Japan, Taiwan, United States, Australia, Singapore, Spain, Germany, Korea, Republic of, Argentina, Canada, France, Hungary, Israel, Lebanon, Thailand
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Novartis PharmaceuticalsCompletedEsophageal Cancer | Triple Negative Breast Cancer | Head & Neck CancerFrance, Singapore, Italy, Japan, United States, Spain
-
Hoffmann-La RocheCompletedTriple-Negative Breast CancerIsrael, United States, Australia, Korea, Republic of, Belgium, Argentina, Denmark, Finland, Italy, Portugal, Spain, Taiwan, Thailand, Japan, United Kingdom, Brazil, Canada, Colombia, Mexico, France, Costa Rica, Switzerland, Czechia, P... and more
-
Gilead SciencesRecruitingTriple Negative Breast Cancer | PD-L1 NegativeUnited States, Hong Kong, Belgium, Australia, Austria, Israel, Spain, Korea, Republic of, Taiwan, China, Japan, Netherlands, Brazil, Canada, Turkey, France, Germany, Malaysia, United Kingdom, Singapore, Hungary, Mexico, Italy, Switzer... and more
-
Hoffmann-La RocheCompletedBreast CancerUnited States, Korea, Republic of, Canada, United Kingdom, Australia, Belgium, Brazil, France, Slovenia, Spain, Taiwan, Japan, Italy, Argentina, India, Germany, Hungary, Russian Federation, Singapore, Ukraine, Costa Rica, Czechia, G... and more
-
Novartis PharmaceuticalsCompletedColorectal Cancer, Triple Negative Breast Cancer, NSCLC - AdenocarcinomaUnited States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
-
Hoffmann-La RocheCompletedTriple Negative Breast CancerUnited States, Korea, Republic of, Belgium, Canada, Germany, United Kingdom, Argentina, Australia, Brazil, Finland, France, Greece, Hungary, Poland, Slovenia, Spain, Taiwan, Turkey, Japan, Singapore, Colombia, Bosnia and Herzegovina, Guatema... and more
-
Hoffmann-La RocheBreast International Group; Frontier Science & Technology Research Foundation... and other collaboratorsCompletedTriple Negative Breast CancerRussian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, Spain, United Kingdom, Korea, Republic of, Philippines, Canada, Germany, Italy, Poland, Belgium, Mexico, Japan, France, Brazil, Taiwan, Thailand, Hungary, Turkey, China, India, South Africa, Singapore, Argentina
-
Novartis PharmaceuticalsTerminatedAdvanced or Metastatic ER+ Breast CancerUnited States, France, Germany, Singapore, Italy, Japan, Belgium
-
AstraZenecaDaiichi SankyoRecruitingBreast CancerUnited States, Spain, China, Italy, Australia, United Kingdom, Korea, Republic of, Vietnam, Japan, Turkey, Brazil, Taiwan, Thailand, Canada, Argentina, India, France, Singapore, Mexico, Germany, Philippines, Poland, South Africa
-
Novartis PharmaceuticalsTerminatedOvarian Cancer | Non-small Cell Lung Cancer (NSCLC) | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Colorectal Cancer Microsatellite Stable (MSS)Canada, Australia, Singapore, United States, Japan, Spain, United Kingdom
-
AstraZenecaActive, not recruitingCervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 PositiveUnited States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
-
Novartis PharmaceuticalsActive, not recruitingAdvanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part SarcomaUnited States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France
-
AstraZenecaCompletedAdvanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast CancerCanada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Puma Biotechnology, Inc.CompletedHER2+ Metastatic Breast Cancer (MBC)United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
-
Novartis PharmaceuticalsTerminatedMelanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
-
MacroGenicsZai Lab (Shanghai) Co., Ltd.Active, not recruitingGastric Cancer | Gastroesophageal Junction Cancer | HER2-positive Gastric CancerKorea, Republic of, United States, China, Italy, Taiwan, Germany, Singapore, United Kingdom, Poland
-
National Cancer Center, JapanRecruitingCervical Cancer | Nasopharyngeal Carcinoma | Ovarian Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Clear Cell CarcinomaJapan, Korea, Republic of, Malaysia, Thailand, Philippines, Singapore, Taiwan, Vietnam
-
Novartis PharmaceuticalsRecruitingCarcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States